RxDoctor Payments Data

Deborah Toppmeyer

Medical Oncology · New Brunswick, NJNPI 1114004975

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $19,305 of the $20,646 with a category attached, or 93.5%. 7 manufacturers reported payments, led by Seagen Inc. at 34.9% of the total. Reporting peaked in 2019 at $20,488 and has fallen 99.4% since, to $114 in 2025.

$20,646in general payments, 2019–2025

Across 17 payments — averaging $1214.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$7K
  • Genentech USA, Inc.$7K
  • Novartis$7K
  • Genentech, Inc.$69
  • Daiichi Sankyo Inc.$45
  • Pfizer$32
  • plus $12 from 1 others
$205,224in research payments, 2019–2025

Across 26 payments — averaging $7893.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$157K
  • Genentech, Inc.$24K
  • Novartis$21K
  • Pfizer$3K

What the payments were for

  • Consulting fees$19,30594%
  • Travel & lodging$1,0285%
  • Food & beverage$2241%
  • Education$890%

General payments by program year

19
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Seagen Inc.3$7,200
Genentech USA, Inc.4$6,721
Novartis5$6,567
Genentech, Inc.1$69
Daiichi Sankyo Inc.2$45
Pfizer1$32
Gilead1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,646 in reported general payments places this provider in the 80th percentile of 112 medical oncology providers in New Jersey.

See all medical oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$35,919
Medicare patients
177
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib18$250,815
KisqaliRibociclib Succinate18$238,991
Anastrozole121$3,149
Letrozole83$1,696
Tamoxifen Citrate62$1,663
Exemestane11$1,009
Gabapentin11$199
Sertraline Hcl12$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$32$250,81518 claims
NovartisKisqali$6,567$238,99118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 112 medical oncology providers in New Jersey.

Other medical oncology in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →